









Markets
/
Stocks
/
nasdaq-bbio
/

BridgeBio Pharma Inc

BBIO

61.370USD

-0.610-0.98%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

11.82BMarket Cap

LossP/E TTM



BridgeBio Pharma Inc

61.370

-0.610-0.98%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of BridgeBio Pharma Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BridgeBio Pharma Inc's Score

Industry at a Glance

Industry Ranking

26 / 159

Overall Ranking

72 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 19 analysts

Buy

Current Rating

80.801

Target Price

+30.37%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

BridgeBio Pharma Inc Highlights

StrengthsRisks

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 185.78% year-on-year.

Undervalued

The company’s latest PE is -14.60, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 193.32M shares, decreasing 0.48% quarter-over-quarter.

Held by Andreas Halvorsen

Star Investor Andreas Halvorsen holds 17.78M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 8.37, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 120.70M, representing a year-over-year increase of 4318.01%, while its net profit experienced a year-over-year increase of 12.78%.

Score

Industry at a Glance

Previous score

8.37

Change



Financials

6.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.47

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

BridgeBio Pharma Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.77, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -14.60, which is -84.95% below the recent high of -2.20 and -8.55% above the recent low of -15.85.

Score

Industry at a Glance

Previous score

6.77

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 26/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.42, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for BridgeBio Pharma Inc is 81.00, with a high of 110.00 and a low of 42.21.

Score

Industry at a Glance

Previous score

8.42

Change

Support & Resistance

No Data

Analyst Rating

Based on 19 analysts

Buy

Current Rating

80.801

Target Price

+30.37%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

BridgeBio Pharma Inc

BBIO

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 7.57, which is higher than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 69.65 and the support level at 52.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.91

Change

-1.34

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.845

Buy

RSI(14)

60.233

Neutral

STOCH(KDJ)(9,3,3)

55.905

Neutral

ATR(14)

3.217

High Vlolatility

CCI(14)

33.792

Neutral

Williams %R

48.476

Neutral

TRIX(12,20)

0.717

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

63.196

Sell

MA10

60.535

Buy

MA20

58.029

Buy

MA50

54.398

Buy

MA100

50.174

Buy

MA200

42.422

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 100.32%, representing a quarter-over-quarter increase of 0.68%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 17.78M shares, representing 9.23% of shares outstanding, with 30.59% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Viking Global Investors LP

Star Investors

17.78M

-4.42%

The Vanguard Group, Inc.

Star Investors

16.45M

+10.64%

Kohlberg Kravis Roberts & Co. L.P.

13.26M

BlackRock Institutional Trust Company, N.A.

11.89M

+6.39%

Janus Henderson Investors

9.28M

+29.35%

Farallon Capital Management, L.L.C.

7.90M

+37.85%

Kumar (Neil)

6.17M

+0.09%

Aisling Capital Management LP

6.07M

State Street Investment Management (US)

5.90M

+2.56%

Two Sigma Investments, LP

4.02M

+260.34%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 7.57, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 1.27. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.